(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 284.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.58%.
Renovorx's revenue in 2026 is $928,000.On average, 5 Wall Street analysts forecast RNXT's revenue for 2026 to be $170,055,610, with the lowest RNXT revenue forecast at $143,667,671, and the highest RNXT revenue forecast at $198,056,146. On average, 5 Wall Street analysts forecast RNXT's revenue for 2027 to be $881,833,629, with the lowest RNXT revenue forecast at $287,335,341, and the highest RNXT revenue forecast at $1,346,884,413.
In 2028, RNXT is forecast to generate $1,997,237,172 in revenue, with the lowest revenue forecast at $794,386,929 and the highest revenue forecast at $3,559,513,142.